Flickr Albums
Close
21-Nov-14
New data from PARADIGM-HF show Novartis’ heart failure drug LCZ696 keeps patients alive longer and in better health than current gold standard ACE inhibitor (enalapril)
Image
(1)

New analyses presented at the American Heart Association (AHA) Scientific Sessions show that LCZ696 cuts the incidence of sudden deaths, accident and emergency (A&E) visits, hospitalisations, worsening symptoms and the need for more intensive treatment in heart failure patients with reduced ejection fraction versus the ACE inhibitor enalapril (a current gold standard treatment)[i]

 

Data presented earlier this year at the European Society of Cardiology meeting announced LCZ696 demonstrated a 20% reduction in cardiovascular deaths and a 21% reduction in heart failure hospitalisations on top of current best standard of care[i]

 

For the 900,000 people in the UK who have heart failure, there is currently a poor prognosis with 60% of patients dying within five years of diagnosis[ii],[iii]


 

[i] McMurray JJV et al. Angiotensin-Neprilysin Inhibition versus enalapril in heart failure, N Engl J Med 2014; DOI: 10.1056/NEJMoa1409077

[ii] NICE. Clinical Guideline. Chronic heart failure. Available online at http://guidance.nice.org.uk/CG108

[iii] Sutherland K. Bridging the quality gap: heart failure. 2010. Available from:

http://www.health.org.uk/public/cms/75/76/313/583/Bridging%20the%20quality%20gap%20Heart

%20Failure.pdf?realName=cXqFcz.pdf

High Definition broadcast quality video is available for download.
Standard-Definition broadcast quality video is available for download in PAL & NTSC.
Streaming quality video is available for download as WMV,Quicktime or FLV.
Production quality audio files are available for download.
Production quality print images are available for download.
YouTube videos are also associated with this article.
Flickr images are also associated with this article.

Sorry

This content is no longer available.

It may have expired or been deleted.

Related Media

Sorry

This content is no longer available.

It may have expired or been deleted.

For More Information
Disclaimer
Novartis has partnered with TheNewsMarket to provide broadcast-standard video - delivered digitally. To make sure that our assets are available to appropriate audiences, some assets appear locked. These are password protected and can only be accessed by journalists and a select group of users. If you are new to the site, please register. Your information will be verified by our team as quickly as possible. Once approved, you will be sent an email confirming your username and password. If you are an existing user of TheNewsMarket, please contact the Novartis media team for access. You may use non-protected material provided in this section for your personal use or for purposes such as news reporting, teaching, scholarship or research. The assets may not be modified and must display a copyright notice in the name of Novartis (Copyright © Novartis).

The information on these pages was factually accurate on the date of publication. This information remains on Novartis website for historical purposes only. Novartis assumes no duty to update the information to reflect subsequent developments. Readers should not rely upon the information in these pages as current or accurate after their publication dates
 
Flickr Albums
Close
This is an RSS feed intended to be viewed in newsreader or syndicated to another site
SUBSCRIBE:
XML